BridgeBio to present encaleret trial data at ASBMR 2026 meeting

October 6, 2026 4:01 PM

BridgeBio Pharma (Nasdaq: BBIO) will present data from its Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found